Investigational drug · Phase 3
DTaP
Also called: Diphtheria-tetanus-acellular pertussis vaccine
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prevent Whooping Cough, Prevent Diphtheria, Prevent Tetanus.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
125
Any phase or sponsor naming "DTaP"
First trial start
2023
Aug 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DTaP", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prevent Whooping Cough
- Prevent Diphtheria
- Prevent Tetanus
- Diphtheria, Tetanus and Acellular Pertussis
- Diphtheria
- Tetanus
- Pertussis
Largest trials
Live from ClinicalTrials.gov: studies naming "DTaP" as an intervention, largest first.
Bandim Health ProjectAcademic, hospital or other
NCT03142139 · 1,027,559 participants · Start Jan 1, 1997 · Primary completion Dec 31, 2014
Drug: RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib; RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib and 1 more · For: Atopic Dermatitis
GlaxoSmithKlineGSK (GSK)
NCT00146835 · 120,794 participants · Start Apr 2003 · Primary completion Jun 2006
Drug: Pediarix; Licensed DTPa containing vaccine and 1 more · For: Hepatitis B; Poliomyelitis; Diphtheria and 2 more
Neuroganics LLCIndustry
NCT05095844 · 100,000 participants (planned) · Start Mar 15, 2022 · Primary completion Apr 1, 2024
Drug: vaccinated · For: COVID-19; Vaccine Adverse Reaction; Vaccine Reaction and 10 more
Sites: Northglenn, Colorado
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT00804284 · 62,538 participants · Start Sep 2008 · Primary completion Aug 2014
Drug: DTaP-IPV/Hib; Other DTap Vaccines · For: Diphtheria; Tetanus; Pertussis and 1 more
Sites: Oakland, California
- Same-Day Co-Administration of Varicella and Inactivated Hepatitis A Vaccines in Children Aged 12 to 23 Months in Shandong, ChinaNot yet recruiting
Shandong UniversityAcademic, hospital or other
NCT07938151 · 35,000 participants (planned) · Start Nov 2026 · Primary completion May 30, 2028
Drug: Live Attenuated Varicella Vaccine; Inactivated Hepatitis A Vaccine · For: Hepatitis A Vaccine; Varicella Immunisation
Sites: Heze, China
- Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO StudyPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03180034 · 27,945 participants · Start Nov 29, 2017 · Primary completion Aug 21, 2025
Drug: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed; Recombinant Human Papillomavirus Bivalent Vaccine and 1 more · For: Human Papillomavirus Infection; Human Papillomavirus-Related Cervical Carcinoma
Sites: Liberia, Costa Rica
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT00855855 · 20,830 participants · Start Feb 2009 · Primary completion Dec 2014
Drug: DTaP-IPV/Hib · For: Haemophilus Infections; Diphtheria; Tetanus and 2 more
Sites: Albany, California; Martinez, California; San Francisco, California · 59 sites in all
- ESCUDDO Long Term Follow UpPivotal-lookingEnrolling by invitation
National Cancer Institute (NCI)NIH
NCT07706673 · 13,700 participants (planned) · Start Aug 11, 2026 · Primary completion Oct 1, 2030
Drug: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed; Recombinant Human Papillomavirus Nonavalent Vaccine · For: Human Papillomavirus Infection; Human Papillomavirus-Related Malignant Neoplasm
Sites: Liberia, Costa Rica
- Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00806195 · 7,744 participants · Start Dec 2008 · Primary completion Mar 2011
Drug: MenACWY-CRM197; DTaP (Diptheria, Tetanus, Pertussis) Vaccine and 6 more · For: Meningitis; Meningococcal Infection
Sites: Birmingham, Alabama; Dothan, Alabama; Tuscon, Arizona · 153 sites in all
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO TrialPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05237947 · 5,000 participants (planned) · Start Mar 1, 2022 · Primary completion Jan 15, 2027
Drug: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed; Recombinant Human Papillomavirus Bivalent Vaccine and 1 more · For: Human Papillomavirus-Related Cervical Carcinoma
Sites: Liberia, Costa Rica
Newest research
PubMed records naming it or its code names, newest first.
- Adverse reactions following upper arm vs. buttock DTaP vaccination in children: A retrospective observational study in Wuxi, China, 2020-2024.
Yang X, Wang L, Chen Q, et al. · Hum Vaccin Immunother 2026
- Exploring the impact of reimbursement ratios on willingness to vaccinate: A mixed-effects modeling approach using panel data.
Xie L, Xing J, Yan M, et al. · Hum Vaccin Immunother 2026
- Analysis of adverse events following immunization after immunization schedule adjustment for acellular DTaP combined vaccine among 6-year-old children in Hangzhou.
Xie Q, Xu Y, Du J, et al. · Hum Vaccin Immunother 2026
- The mutual effects on safety and immunogenicity of combined vaccination with 15-valent pneumococcal conjugate vaccine and adsorbed acellular DPT in 3-month healthy infants: A randomized, open-label, controlled, phase III clinical trial.
Lu-Lu P, Hong-Ze M, Zhao G, et al. · Hum Vaccin Immunother 2026
- Comparative analysis of adverse events following immunization with DTaP vaccine in children before and after immunization schedule adjustment.
Liu T, Chen Q, Ye C, et al. · Hum Vaccin Immunother 2026
- Immunogenicity and safety of a 2ߙ+ߙ1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
Salamanca de la Cueva I, González López M, Roldán López R, et al. · Hum Vaccin Immunother 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.